Clinical trial
Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia
NCT00425815 · University of California, Los Angeles, Other · Withdrawn
Key facts
| NCT number | NCT00425815 |
|---|---|
| Title | Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia |
| Official title | A Placebo-Controlled Trial of Org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients With Schizophrenia |
| Lead sponsor | University of California, Los Angeles, Other |
| Collaborators | University of Maryland Washington University School of Medicine Massachusetts General Hospital Nathan Kline Institute for Psychiatric Research Columbia University Duke University Beth Israel Deaconess… |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug, Other |
| Interventions | Org 24448, Placebo |
| Enrollment | 0 |
| Start date | Apr 1, 2009 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 23, 2007 |
| Last update posted | Feb 9, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: